For the study, researchers tracked 1,070 kids aged 12 to 18 who were overweight or obese and also had a diagnosis of asthma.

SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an eosinophilic phenotype, according to a press release from GSK.Depemokimab ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. This week’s issue of the prestigious medical journal the Lancet is ...

Asthma is a common prevalent chronic respiratory illness that affects millions of people all over the world in every age group. Asthma is defined as inflamed and constricted airways, causing repeated ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as an add-on maintenance treatment of severe asthma with an eosinophilic ...

Regarding who can use these inhalers, NHS guidelines state: "Most adults can use beclometasone inhalers for asthma or COPD.

Coughing and wheezing can leave anyone wondering whether it is asthma or bronchitis at play. Both of these respiratory issues ...